Australia’s topical absorbable hemostats market is witnessing steady expansion as surgical volumes rise and hospitals increasingly adopt advanced bleeding control solutions to improve procedural efficiency and patient outcomes. Against this backdrop, the topical absorbable hemostats market in Australia is anticipated to grow at a compound annual growth rate (CAGR) of approximately 3% over the forecast period, according to GlobalData, a leading intelligence and productivity platform.

GlobalData’s report, “Topical Absorbable Hemostats Market Size by Segments, Share, Regulatory, Reimbursement, Interventions and Forecast to 2036,” reveals that Australia accounted for nearly 5% of the Asia-Pacific (APAC) topical absorable hemostats market in 2025.

Prerna Gupta, Medical Devices Analyst at GlobalData, comments: “The growing use of topical absorbable hemostats in Australia is fuelled by the demand for improved surgical efficiency, reduction of transfusion needs and technological advancements while ensuring patient safety remains intact. Products that reduce preparation time and integrate seamlessly into existing surgical protocols, such as room-temperature hemostats, are likely to see stronger uptake among clinicians.”

Within this evolving market landscape, the recently approved Baxter Healthcare’s room-temperature Hemopatch Sealing Hemostat is gaining notable traction across Australia and New Zealand. The product’s ready-to-use format eliminates the need for refrigeration, simplifying storage and preparation while enabling faster deployment in operating rooms. This innovation aligns well with the growing demand for efficient and workflow-friendly topical hemostatic solutions.

Hemopatch’s absorbable collagen-based design supports tissue sealing and effective control of mild to moderate bleeding, making it suitable for a wide range of surgical applications. With an extended shelf life of up to 36 months at room temperature, the product offers logistical advantages for healthcare facilities, particularly those managing high surgical throughput or operating across multiple clinical sites.

Gupta concludes: “The Australian market for topical absorbable hemostats is expected to experience steady growth as surgeons become more confident in advanced absorbable hemostatic technologies. Leading products from major firms such as Baxter are bolstering this trust, which in turn creates ongoing opportunities for manufacturers who can address requirements for ease of use in surgical procedures, compliance with regulations, and evolving clinical needs.”